Home Tags ADC

Tag: ADC

Featured Image: Cancer cell Courtesy: © 2018. Fotolia. Used with permission.

Confocal Microscopy and Imaging Flow Cytometry – Tools for Selection of...

Research articleAbstract Antibody-drug Conjugates (ADCs) are a growing class of targeted anti-cancer therapies, that combine the specific binding of an antibody with the toxic effects...
The AACR 2019 Annual Meeting - Poster Session during the American Association for Cancer Research (AACR) Annual Meeting, Sunday March 31, 2019. Courtesy: © AACR/Todd Buchanan 2019

Randall Schatzman, Ph.D. to Lead Growth of Immune-Stimulating Antibody Conjugates at...

Veteran Executive Randall Schatzman, Ph.D. has been hired as the new Chief Executive Officer and a member of the board of directors of Bolt...

World ADC 2019: Maximizing the Clinical Therapeutic Index of Antibody-drug Conjugates

With five approved and commercially available antibody-drug conjugates and nearly 100 in various stages of clinical development, it is exciting to see how the...

WCLC 2019: Daiichi Sankyo to Present Late-breaking Results from U3-1402 and...

The World Health Organization (WHO) estimates that lung cancer causes 1.59 million deaths globally per year. Non-small cell lung cancer (NSCLC) accounts for 80%–90%...
Boston

Conagen Acquires Therapeutic Proteins Production Platform

Boston-based Conagen, a synthetic biology company and a leader in bioengineering, has acquired a fermentation-based technology for the production of therapeutically useful glycoproteins. The...
Featured Image: General views at the American Society for Clinical Oncology (ASCO) annual meeting. Courtesy: © ASCO/Max Gersh 2015. Used with permission.

New Data Demonstrates Potential for RemeGen’s RC48 in HER2+ Cancers

Results from a robust oncology pipeline, including the latest phase II data of an investigational antibody-drug conjugates (ADC) called RC48 being developed by RemeGen...
Courtesy: Fotolia

The Evolving Market for Antibody-drug Conjugates

The scale of patient demand has fueled an overarching healthcare market need to expand the drug development pipeline to generate more biologics to treat...
Featured Image: Lonza, Visp, Switzerland. Courtesy: © 2010 - 2018 Lonza, Visp, Switzerland. Used with permission.

Lonza Expands Manufacturing Capacity for ADC Payloads

Lonza, a specialty contract development and manufacturing (CDMO) partner to the biopharma industry, will add new highly potent API (HPAPI) manufacturing suites at its...

Evolution of Antibody-Drug Manufacturing

Antibody-drug Conjugates (ADCs) have evolved since the initial approval of gemtuzumab ozogamicin (Mylotarg®) in 2000, with respect to conjugation, linker and toxin chemistries and...

ADCs – Look Forward to a Potent Future

Antibody-drug conjugation (ADC) technology has been around for several decades but has yet to reach its full potential in terms of clinical success. In...